Key Insights

Highlights

Success Rate

73% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

15.8%

3 terminated out of 19 trials

Success Rate

72.7%

-13.8% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

75%

6 of 8 completed with results

Key Signals

6 with results73% success

Data Visualizations

Phase Distribution

7Total
Not Applicable (1)
P 1 (1)
P 2 (4)
P 3 (1)

Trial Status

Completed8
Unknown4
Terminated3
Enrolling By Invitation2
Recruiting2

Trial Success Rate

72.7%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT07455864RecruitingPrimary

Lysosomal Acid Lipase Deficiency in Risk Groups

NCT01633489RecruitingPrimary

Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT05368038Enrolling By Invitation

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

NCT05687474Completed

Baby Detect : Genomic Newborn Screening

NCT03655223Enrolling By Invitation

Early Check: Expanded Screening in Newborns

NCT03984149UnknownPrimary

Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)

NCT01757184Phase 3CompletedPrimary

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

NCT03564002UnknownPrimary

Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity

NCT02112994Phase 2CompletedPrimary

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

NCT02193867Phase 2TerminatedPrimary

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT01371825Phase 2CompletedPrimary

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01307098Phase 1Completed

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

NCT01488097Phase 2Completed

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

NCT02926872TerminatedPrimary

Screening for Lysosomal Acid Lipase Deficiency

NCT01528917Completed

An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype

NCT01358370CompletedPrimary

A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype

NCT02376751UnknownPrimary

An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

NCT02345421TerminatedPrimary

A Study to Identify and Characterize LAL-D Patients in High-risk Populations

NCT01716728Not ApplicableUnknownPrimary

Identification of Undiagnosed Lysosomal Acid Lipase Deficiency

Showing all 19 trials

Research Network

Activity Timeline